Resistance and DNA repair mechanisms of cancer stem cells: Potential molecular targets for therapy

DNA Repair of Cancer Stem Cells

Volumn 9789400745902, Issue , 2013, Pages 33-52

  Ahmad, Aamir ^a   Li, Yiwei ^a   Bao, Bin ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902457225     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-4590-2_3     Document Type: Chapter

References (131)

1. Siegel R,Ward E, Brawley O, JemalA(2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
3. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL,Wahl GM (2006) Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339-9344
4. Farnie G, Clarke RB (2007) Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 3:169-175
5. Wang Z, LiY, Banerjee S, Sarkar FH (2009) Emerging role of Notch in stem cells and cancer. Cancer Lett 279:8-12
6. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16:3141-152
7. Katoh M, Katoh M (2007) WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13:4042-4045
8. KatohY, KatohM(2006) Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). Int J Mol Med 18:1019-1023
9. MedinaV, Calvo MB, az-Prado S, Espada, J (2009) Hedgehog signalling as a target in cancer stem cells. Clin Transl Oncol 11:199-207
10. Cerdan C, BhatiaM(2010) Novel roles for Notch, Wnt and Hedgehog in hematopoesis derived from human pluripotent stem cells. Int J Dev Biol 54:955-963
11. Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97-106
12. Mathews LA, Cabarcas SM, Farrar WL (2011) DNA repair: the culprit for tumor-initiating cell survival? Cancer Metastasis Rev 30:185-197
13. Blanpain C, Mohrin M, Sotiropoulou PA, Passegue E (2011)DNA-damage response in tissuespecific and cancer stem cells. Cell Stem Cell 8:16-29
14. Lacerda L, Pusztai L,WoodwardWA(2010)The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat 13:99-108
15. Wang Z, LiY, Ahmad A, Azmi AS, Kong D, Banerje S, Sarkar FH (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 13:109-118
16. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284
17. Moore N, Lyle S (2011) Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol (PMID: 20936110; doi: 10.1155/2011/ 396076, http://www.hindawi.com/journals/jo/2011/396076/)
18. Viale A, Pelicci PG (2009) Awaking stem cells from dormancy: growing old and fighting cancer. EMBO Mol Med 1:88-91
19. Li L, Bhatia R (2011) Stem cell quiescence. Clin Cancer Res 17:4936-4941
20. Dembinski JL, Kraus S (2009) Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 26:611-623
21. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH (2010) CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29:2672-2680
22. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M (2010)A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-594
23. Forsberg EC, Passegue E, Prohaska SS,Wagers AJ, Koeva M, Stuart JM,Weissman IL (2010) Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS One 5:e8785
24. Ichihara E, Kaneda K, SaitoY,Yamakawa N, Morishita K (2011) Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells. Biochem Biophys Res Commun 416:239-245
25. Roth S, Fodde R (2011) Quiescent stem cells in intestinal homeostasis and cancer. Cell Commun Adhes 18:33-44
26. Buczacki S, Davies RJ, Winton DJ (2011) Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target. Br J Cancer 105:1253-1259
27. Havard M, Dautry F, Tchenio T (2011) A dormant state modulated by osmotic pressure controls clonogenicity of prostate cancer cells. J Biol Chem 286:44177-44186
28. Dean M, Allikmets R (1995) Evolution ofATP-binding cassette transporter genes. Curr Opin Genet Dev 5:779-785
29. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATPdependent transporters. Nat Rev Cancer 2:48-58
30. Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14:3-9
31. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004-3008
32. Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507-512
33. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K. (2002) The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8:22-28
34. Lou H, DeanM(2007) Targeted therapy for cancer stem cells: the patched pathway andABC transporters. Oncogene 26:1357-1360
35. AnY, OngkekoWM(2009) ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5:1529-1542
36. Elliot A, Adams J, Al-Haj M (2010) The ABCs of cancer stem cell drug resistance. I Drugs 13:632-635
37. Loebinger MR, Giangreco A, Groot KR, Prichard L, Allen K, Simpson C, Bazley L, Navani N, Tibrewal S, Davies D, Janes SM (2008) Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br J Cancer 98:380-387
38. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4:226-235
39. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J (2010) Cancer stem/progenitor cells are highly enriched in CD133+ CD44+ population in hepatocellular carcinoma. Int J Cancer 126:2067-2078
40. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, Brown R (2011) Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10:325-335
41. Jeong HW, CuiW,Yang,Y, Lu J, He J, Li A, Song D, GuoY, Liu BH, Chai L (2011) SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS One 6:e18372
42. Schinkel AH, Smit JJ, van TO, Beijnen JH,Wagenaar E, van DL, Mol CA, van dV Robanus-Maandag EC, te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
43. Moitra K, Lou H, DeanM(2011) Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89:491-502
44. Lee CH (2010) Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 596:325-340
45. Hambardzumyan D, Squatrito M, Holland EC (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10:454-456
46. Vlashi E, McBride WH, Pajonk F (2009) Radiation responses of cancer stem cells. J Cell Biochem 108:339-342
47. Bauman M, Krause M, Hil R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8:545-554
48. Bao S,Wu Q, McLendon RE, HaoY, Shi Q, Hjelmeland AB, DewhirstMW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760
49. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777-1785
50. WoodwardWA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM (2007) WNT/betacatenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104:618-623
51. Bao S,Wu Q, Sathornsumete S, HaoY, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843-7848
52. Rich JN (2007) Cancer stem cells in radiation resistance. Cancer Res 67:8980-8984
53. Gieni RS, Ismail IH, Campbel S, Hendzel MJ (2011) Polycomb group proteins in the DNA damage response: a link between radiation resistance and "stemness". Cell Cycle 10:883-894
54. Facchino S, Abdouh M, ChatoW, Bernier G (2010) BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 30:10096-10111
55. Yin H, Glas J (2011) The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One 6:e24080
56. Wei L, Liu TT,Wang HH, Hong HM,Yu AL, Feng HP, ChangWW(2011) Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-kappa B. Breast Cancer Res 13:R101
57. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, Bapat SA (2009) Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27:2059-2068
58. Saigusa S, Tanaka K, ToiyamaY,Yokoe T, OkugawaY, IoueY, Miki C, Kusunoki M (2009) Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16:3488-3498
59. Yu CC, Chiou GY, LeYY, ChangYL, Huang PI, ChengYW, Tai LK, Ku HH, Chiou SH,Wong TT (2010) Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAILinduced apoptosis and radiosensitivity. Childs Nerv Syst 26:897-904
60. Mihatsch J, Toulany M, Bareis PM, Grim S, Lengerke C, Kehlbach R, Rodeman HP (2011) Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother Oncol 99:300-306
61. Croker AK, Allan AL (2012) Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat 133:75-87
62. D'Andrea FP, Safwat A, Kassem M, Gautier L, Overgaard J, Horsman MR (2011) Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiother Oncol 99:373-378
63. Choi S, Ku JL (2011) Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. Biochem Biophys Res Commun 412:207-213
64. Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T, Lin J (2011) STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells. Biochem Biophys Res Commun 416:246-251
65. Kim RK, Yoon CH, Hyun KH, Le H, An S, Park MJ, Kim MJ, Le SJ (2010) Role of lymphocyte-specific protein tyrosine kinase (LCK) in the expansion of glioma-initiating cells by fractionated radiation. Biochem Biophys Res Commun 402:631-636
66. Ma HI, Chiou SH, Hueng DY, Tai LK, Huang PI, Kao CL, Chen YW, Sytwu HK (2011) Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Lab Inves J Neurosurg 114:651-662.
67. ZhuangW, Li B, Long L, Chen L, Huang Q, Liang Z (2011) Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 129:2720-2731
68. KimY, Kim KH, Le J, LeYA, Kim M, Le SJ, Park K,Yang H, Jin J, Jo KM, Le J, Nam DH (2012) Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 92:466-473
69. YangYP, ChienY, Chiou GY, Cherng JY,Wang ML, Lo WL, ChangYL, Huang PI, ChenYW, ShihYH, ChenMT, ChiouSH(2012) Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 33:1462-1476
70. Pajonk F, Vlashi E, McBride WH (2010) Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28:639-648
71. Debeb BG, Xu W, Woodward WA (2009) Radiation resistance of breast cancer stem cells: understanding the clinical framework. J Mammary Gland Biol Neoplasia 14:11-17
72. Cripe TP, Wang PY, Marcato P, Mahller YY, Le PW (2009) Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 17:1677-1682
73. Frosina G (2009) DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 7:989-999
74. Morrison R, Schleicher SM, SunY, Nierman KJ, Kim S, Sprat DE, Chung CH, Lu B (2011) Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011:941876
75. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440-450
76. XuY, Price BD (2011) Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle 10:261-267
77. Rossetto D, Truman AW, Kron SJ, Cote J (2010) Epigenetic modifications in double-strand break DNA damage signaling and repair. Clin Cancer Res 16:4543-4552
78. Frosina G (2009) DNA repair in normal and cancer stem cells, with special reference to the central nervous system. Curr Med Chem 16:854-866
79. Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A, Poggi A, Cappelli E, Zona G, Spaziante R, Corte G, Frosina G (2009) Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 7:383-392
80. Jalal S, Earley JN, Turchi JJ (2011) DNA repair: from genome maintenance to biomarker and therapeutic target. Clin Cancer Res 17:6973-6984
81. Frosina G (2010) The bright and the dark sides of DNA repair in stem cells. J Biomed Biotechnol 2010:845396
82. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23
83. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320
84. Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cellspotential partners in glioma drug resistance? Cancer Treat Rev 34:558-567
85. Di BG, Alessio N, Dell'Aversana C, Casale F, Teti D, Cipollaro M, Altucci L, Galderisi U (2010) Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 225:537-544
86. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizi M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, Duranti E, Martinelli S, Rinaldo C, Zeuner A, Maugeri-Sacca M, Eramo A, De MR (2012) Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 19:768-778
87. VialeA, De FF, OrlethA, CambiaghiV, GiulianiV, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, Gobbi A, Alcalay M, Minucci S, Pelicci PG (2009) Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457:51-56
88. Zhuang W, Li B, Long L, Chen L, Huang Q, Liang ZQ (2011) Knockdown of the DNAdependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. Brain Res 1371:7-15
89. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M (2010) Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 12:R31
90. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrel F, Edwards D, Medina D, TsimelzonA, Hilsenbeck S, Green JE, MichalowskaAM, RosenJM(2008) Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 68:4674-4682
91. Fan J, Robert C, JangYY, Liu H, Sharkis S, Baylin SB, Rassool FV (2011) Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels ofDNArepair and efficacy of nonhomologous end-joining. Mutat Res 713:8-17
92. Sarkar FH, LiY,Wang Z, Kong D (2009) Cellular signaling perturbation by natural products. Cell Signal 21:1541-1547
93. Sarkar FH, LiY (2009) Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35:597-607
94. Sarkar FH, LiY, Wang Z, Padhye S (2010) Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des 16:1801-1812
95. Sarkar FH, LiY,Wang Z, Kong D (2010) The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev 29:383-394
96. Kawasaki BT, Hurt EM, Mistre T, Farrar WL (2008) Targeting cancer stem cells with phytochemicals. Mol Interv 8:174-184
97. LiY,Wicha MS, Schwartz SJ, Sun D (2011) Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem 22:799-806
98. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N (2010) What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 15:668-678
99. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105:4163-169
100. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbet CA, Hassane DC, BeckerMW, Bennet JM, Sullivan E, Lachowicz JL,Vaughan A, Sweeney CJ, MatthewsW, Carrol M, Liesveld JL, Crooks PA, JordanCT(2007)Anorally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110:4427-4435
101. KimYR, Eom JI, Kim SJ, Jeung HK, Cheong JW, Kim JS, MinYH (2010) Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther 335:389-400
102. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, ZhangY (2008) NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111:419-427
103. LiuY, Lu WL, Guo J, Du J, Li T,Wu JW,Wang GL,Wang JC, Zhang X, Zhang Q (2008) A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 129:18-25
104. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, KimYS, FarrarWL(2009) Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. Prostate 69:827-837
105. Zuch D, GiangAH, ShapovalovY, Schwarz E, Rosier R, O'Keefe R, EliseevRA(2011)Targeting radioresistant osteosarcoma cells with parthenolide. J Cell Biochem (PMID: 22109788; doi: 10.1002/jcb.24002)
106. Gun EJ, Williams JT, Huynh, DT, Iannotti MJ, Han C, Barrios FJ, Kendal S, Glackin CA, Colby DA, Kirshner J (2011) The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma. Leuk Lymphoma 52:1085-1097
107. Volate SR, Kawasaki BT, Hurt EM, Milner JA, KimYS, White J, FarrarWL (2010) Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol Cancer Ther 9:461-470
108. Denissova NG, Nasello CM, Yeung PL, Tischfield JA, Brenneman MA (2012) Resveratrol protects mouse embryonic stem cells from ionizing radiation by accelerating recovery from DNA strand breakage. Carcinogenesis 33:149-155
109. Lu KH, ChenYW, Tsai PH, Tsai ML, Le YY, Chiang CY, Kao CL, Chiou SH, Ku HH, Lin CH, ChenYJ (2009) Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv Syst 25:543-550
110. YangYP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH, Chen MH, Chen MT, Shih YH, Chang CH, Hsu CC, Ma HI, Wang CT, Tsai LL, Yu CC, Chang CJ (2012) Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 227:976-993
111. Pandey PR, Okuda H,Watabe M, Pai SK, LiuW, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, Wakabayashi G, Koeda K, Kashiwaba M, Suzuki K, Chiba T, Endo M, Fujioka T, Tanji S, MoYY, Cao D,WilberAC,Watabe K (2011) Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat 130:387-398
112. Shankar S, Nal D,Tang SN, Meeker D, Passarini J, Sharma J, SrivastavaRK(2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6:e16530
113. LiY, Zhang T, Korkaya H, Liu S, Le HF, Newman B,YuY, Clouthier SG, Schwartz SJ,Wicha MS, Sun D (2010) Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 16:2580-2590
114. Rausch V, Liu L, Kallifatidis G, Bauman B, Mattern J, Gladkich J, Wirth T, Schemmer P, Buchler MW, Zoller M, Salnikov AV, Her I (2010) Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70:5004-5013
115. Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Buchler MW, Salnikov AV, Her I (2011) Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 19:188-195
116. Srivastava RK, Tang SN, ZhuW, Meeker D, Shankar S (2011) Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front Biosci (Elite Ed) 3:515-528
117. ZhouW, Kallifatidis G, Bauman B, Rausch V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Buchler MW, Salnikov AV, Her I (2010) Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol 37:551-561
118. Tang SN, Singh C, Nal D,Meeker D, Shankar S, SrivastavaRK(2010)The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 5:14
119. Tang SN, Fu J, Nal D, Rodova M, Shankar S, Srivastava RK (2012) Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer 131:30-40
120. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G,Wicha MS (2010) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat 122:777-785
121. YuY, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, MajumdarAP (2009) Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2:321-328
122. Fong D, Yeh A, Naftalovich R, Choi TH, Chan MM (2010) Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 293:65-72
123. Padhye S,Yang H, Jamadar A, Cui QC, Chavan D, Dominiak K, McKinney J, Banerje S, Dou QP, Sarkar FH (2009) New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res 26:1874-1880
124. Padhye S, Banerje S, Chavan D, Pandye S, Swamy KV, Ali S, Li J, Dou QP, Sarkar FH (2009) Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 26:2438-2445
125. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, Majumdar AP (2011) Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 28:827-838
126. Bao B, Ali S, Kong D, Sarkar SH,Wang Z, Banerje S, Aboukameel A, Padhye S, Philip PA, Sarkar FH (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 6:e17850
127. Bao B, Ali S, Banerje S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH (2012) Curcumin analog CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72:335-345
128. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG (2011)Apolymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 11:464-473
129. Lin L, LiuY, Li H, Li PK, Fuchs J, Shibata H, IwabuchiY, Lin J (2011) Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer 105:212-20
130. Freitas AA, de Magalhaes JP (2011) A review and appraisal of the DNA damage theory of ageing. Mutat Res 728:12-22
131. Hoeijmakers JH (2009) DNA damage, aging, and cancer. N Engl J Med 361:1475-1485